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Dogs can spontaneously develop complex systemic autoimmune disorders, with similarities to human 
autoimmune disease. Autoantibodies directed at self-antigens are a key feature of these autoimmune 
diseases. Here we report the identification of interleukin enhancer-binding factors 2 and 3 (ILF2 and 
ILF3) as autoantigens in canine immune-mediated rheumatic disease. The ILF2 autoantibodies were 
discovered in a small, selected canine cohort through the use of human protein arrays; a method not 
previously described in dogs. Subsequently, ILF3 autoantibodies were also identified in the same 
cohort. The results were validated with an independent method in a larger cohort of dogs. ILF2 and 
ILF3 autoantibodies were found exclusively, and at a high frequency, in dogs that showed a speckled 
pattern of antinuclear antibodies on immunofluorescence. ILF2 and ILF3 autoantibodies were also 
found at low frequency in human patients with SLE and Sjögren’s syndrome. These autoantibodies have 
the potential to be used as diagnostic biomarkers for canine, and possibly also human, autoimmune 
disease.
Autoimmune disorders are a diverse group of diseases affecting humans, dogs and other animals1. One impor-
tant characteristic of autoimmune disease is the presence of autoantibodies directed against self-antigens. 
Autoantibodies can be pathogenic, for example, by forming immune-complexes that can deposit in different 
tissues and cause inflammation2. However they are not always direct pathogenic, but can in some instances be 
markers of cell-mediated autoimmunity3. In addition to providing insight into disease pathogenesis, autoantibod-
ies can serve as diagnostic and prognostic markers4–6. Autoantibody analyses can also be used to stratify patients 
into etiologically homogenous subgroups, which can facilitate research and clinical management.
Dogs of several breeds are predisposed to develop complex autoimmune disorders, such as systemic lupus 
erythematosus (SLE) and other systemic rheumatic diseases7–9 and are considered a suitable model for studying 
complex diseases affecting both humans and dogs10. Although the term SLE is widely used in veterinary litera-
ture to describe a multi-systemic autoimmune disease, different diagnostic critera are used11,12, and the diseases 
are not necessarly identical, in humans and dogs. The Nova Scotia duck tolling retriever (NSDTR), is a breed 
particularly affected by immune-mediated rheumatic disease (IMRD)13. This is an SLE-related disease character-
ised by chronic stiffness and pain from multiple joints caused by non-erosive polyarthritis, and the presence of 
autoantibodies directed to nuclear antigens, called antinuclear antibodies (ANA). These ANA are also commonly 
present in both human and canine SLE and other systemic rheumatic diseases11,14,15. Several genetic risk factors 
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for IMRD have been identified16,17. Interestingly, particular subgroups of ANA are associated with different, but 
overlapping sets of genes in dogs18.
Autoantibodies are often directed at proteins that are highly conserved between species19. The standard test for 
detecting canine ANA – indirect immunofluorescence microscopy (IIF) – uses cells of human origin (HEp-2) as 
substrate20. In a previous study, it could be shown that several autoantibodies with important roles in human dis-
ease were also present in dogs21. Thus, the autoantibody targets in human and canine disease frequently overlap, 
although there are some autoantibodies that are species-specific22.
Developments in proteomic technologies have opened for new ways to study autoimmune diseases. Human 
protein arrays, which contain thousands of full-length proteins, have been successfully used to identify novel 
autoantibody targets in human autoimmune diseases23–26. The main aim of the present study was to use protein 
arrays to identify new autoantigens in canine autoimmune disease.
Results
ILF2 is an autoantigen in ANA positive dogs with IMRD. A panel of approximately 17,000 human full-
length proteins was used to identify autoantigens in ANA positive dogs with IMRD. The workflow of the study 
is presented in Supplementary Fig. 1. In the discovery phase, we focused our studies on two subgroups of these 
IMRD patients with different ANA patterns on IIF: speckled (ANAS) and homogenous (ANAH). Sera from nine 
canine patients with ANAS, three with ANAH, and nine healthy controls were used to screen the protein arrays 
(Supplementary Table 1). All the ANAS sera had tested negative for reactivity to 18 known autoantigens, meaning 
that a broad screen would have the potential to uncover previously undetected autoantigens (Supplementary 
Fig. 2). To select for patient-associated autoantibody signals, we used a cutoff value, based on the healthy controls, 
of the mean + 3 SD (log-transformed data) for each antigen. Low level signals (below the mean + 3 SD for each 
sample) were removed. This approach identified 90 antigens with increased autoantibody signals in at least one 
IMRD patient. To search for common antigen-targets, we excluded antigens with autoantibody signals present 
in only one of the patients. This identified seven autoantigens (ILF2, FAM134B, CCDC97, ETFB, PAIP2, CTDP1 
and NUBP1), of which ILF2 was the most promising candidate autoantigen. ILF2 autoantibodies were detected in 
seven of the nine IMRD patients with ANAS, but were absent in all patients with ANAH and the healthy controls 
(Fig. 1). In comparison, signals to the second most common target, FAM134B, were present in only three of the 
12 IMRD patients.
We next sought to validate ILF2 as a bona fide autoantigen using an independent method. Recombinant 
radio-labelled ILF2 was expressed in vitro and immunoprecipitated with patient and control sera. The 
radio-ligand binding assay (RLBA) confirmed the results of the protein array screen. It identified all of the sera 
from IMRD ANAS patients (i.e., the discovery cohort) as ILF2-positive and all the patients with ANAH and 
healthy controls as negative (cutoff = mean + 5 SD of healthy controls) (Fig. 2a). Because it appeared that ILF2 
was a common autoantigen in the IMRD ANAS patients, we screened an extended cohort of NSDTRs with IMRD 
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Figure 1. Identification of ILF2 as a potential autoantigen in canine IMRD. ILF2 was identified as a potential 
autoantigen in canine immune-mediated rheumatic disease (IMRD) by a protein array screen of 12 IMRD 
patients and 9 healthy controls. All of the dogs were of the breed Nova Scotia duck tolling retriever (NSDTR). 
Log(ln)-transformed fluorescence signal intensities are the mean of protein duplicates. The cutoff value was 
calculated from healthy controls as the mean + 3 SD (ln-transformed data). IMRD ANAS, IMRD patients with 
speckled antinuclear antibodies (ANA) pattern. IMRD ANAH, IMRD patients with homogenous ANA pattern.
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were considered together, ILF2 autoantibodies were present in 27 of 29 (93.1%) ANAS sera from NSDTRs with 
IMRD (Fig. 2b). In the extended cohort we also screened 121 ANAS sera from 43 other breeds where the dog was 
suspected to have an autoimmune disease. In these samples, 49 (40.5%) of the sera were ILF2-positive (Fig. 2b). 
A marked difference was obvious between breeds in the frequency of ILF2 autoantibodies when comparing two 
of the most prevalent breeds in the study (Supplementary Table 2). While all 18 cocker spaniels had ILF2 autoan-
tibodies, only one of the 20 German shepherd dogs was ILF2-positive. Furthermore, ILF2 autoantibodies were 
exclusively found in ANAS sera; they were not present in sera from the 84 healthy controls or in the 57 patients 
with IMRD ANAH, IMRD without ANA, or with steroid-responsive meningitis-arteritis (Fig. 2b).
Autoantibodies to ILF2 and ILF3 are found in association. The ILF2 protein is expressed predomi-
nantly in the nucleus as a heterodimer complex with ILF327. Because of this association, we asked whether ILF3 
might also be a target of autoantibodies in the IMRD patients. RLBA was used to screen the canine cohort for 
ILF3 autoantibodies. As with the ILF2 autoantibodies, ILF3 autoantibodies were present only in ANAS sera – in 
26 of 29 (89.7%) of the NSDTRs with IMRD and in 41 of 120 (34.2%) of the ANAS from dogs of other breeds, 
including German shepherd dogs and cocker spaniels (Fig. 3a). All cocker spaniel sera (n = 18) were above base-
line, with 13 sera testing positive above the cutoff value.
ILF2 and ILF3 proteins are also known to form complexes with other proteins, including RNA-binding 
motif protein, X chromosome – RBMX (also known as hnRNP G)28,29. Interestingly, RBMX has previously been 
described as an autoantigen in dogs with lupus-like disease and ANAS22,30. To better understand the relation 
between RBMX autoantibodies and those of ILF2 or ILF3, we screened the total canine cohort (discovery and 
extended) for RBMX autoantibodies. Autoantibodies to RBMX were detected in 14 of 18 ANAS sera from the 
German shepherd dogs, and in five of the 83 ANAS serum samples from other breeds (Fig. 3b). Of these five 
RBMX-positive dogs, four were cross-breeds and one dog of unknown breed. Only one of the 19 RBMX-positive 
dogs also had autoantibodies to ILF3, while no dog was positive for both RBMX and ILF2 (Fig. 4).
In total, 289 samples were analysed for autoantibodies to the three antigens: 66 were positive for both ILF2 and 
ILF3 and 10 were exclusively ILF2-positive (Fig. 4). None of the sera were positive for ILF3 only, or for all three 
antigens. Of the 148 ANAS samples analysed for autoantibodies to all three antigens, 95 (64.2%) were positive for 
at least one antigen and 77 (52.0%) for ILF2 and/or ILF3. Because ILF2 and ILF3 autoantibodies often co-existed 
in patients, we investigated the possibility of cross-reactivity using an immune competition approach. Labelled 
in vitro translated proteins at a constant concentration (1 U ≈ 30,000 cpm), and unlabelled proteins at increasing 
concentrations (1 to 32 U), were allowed to react with ILF2- and ILF3-positive sera. The ILF2 immunoreactivity 
was not reduced by unlabelled ILF3, and vice versa, i.e., ILF3 immunoreactivity was not reduced or eliminated 
by unlabelled ILF2 (Supplementary Fig. 3). As expected, the ILF2 immune reactivity could be eliminated by 
increasing concentrations of unlabelled ILF2 and that of ILF3 by increasing concentrations of unlabelled ILF3.
To illustrate the type of staining pattern of ILF2- and ILF3-positive sera, we stained HEp-2 cells with the 
autoantibody-positive canine sera and had the images evaluated by an experienced interpreter. Incubation with 
Figure 2. Validation of ILF2 with an independent method. Radio-ligand binding assay was used to validate 
ILF2 as an autoantigen in the discovery cohort (a) and in an extended cohort. (b) represent discovery and 
extended cohort together. All of the patients with immune-mediated rheumatic disease (IMRD) were of the 
breed Nova Scotia duck tolling retriever (NSDTR). The cutoff value was calculated from healthy controls as the 
mean + 5 SD. All samples were analysed in duplicate. Autoantibody index = (sample value mean − negative 
control)/(positive control − negative control) * 100. IMRD ANAS, IMRD patients with speckled antinuclear 
antibodies (ANA) pattern IMRD. ANAH, IMRD patients with homogenous ANA pattern IMRD. ANAneg, IMRD 
patients without ANA. SRMA, steroid-responsive meningitis-arteritis.
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the ILF2- and ILF3-positive sera showed tiny speckles across all nucleoplasm in which neither the chromatin 
mass of mitotic cells nor the nucleoli took up the stain (Fig. 5a). This was interpreted as a fine-speckled ANA 
pattern, AC-431. We also performed IIF with commercial ILF2 and ILF3 antibodies, which displayed a similar fine 
speckled staining pattern (AC-4); here, however, some but not all nucleoli were stained (Fig. 5b and c).
Screening of human patients with SLE or Sjögren’s syndrome for ILF2 and ILF3 autoantibodies. 
To assess the presence of ILF2 and ILF3 autoantibodies in human disease, we screened human sera from patients 
with SLE, Sjögren’s syndrome or systemic sclerosis (scleroderma) (Supplementary Fig. 4). Autoantibodies to ILF2 
were detected in one Sjögren’s syndrome patient, and at a level just above cutoff in one SLE patient. Similarly, ILF3 
autoantibodies were detected in a different Sjögren’s syndrome patient and in two other SLE patients, but again 
close to the cutoff level. All healthy controls were negative for both ILF2 and ILF3 autoantibodies.
Discussion
Here we identified ILF2 and ILF3 as major autoantigens in canine systemic autoimmune disease. These two 
proteins are expressed as heterodimers in many tissues where they function as transcription factors crucial 
for expression of, for example, interleukin-2 and interleukin-1327,32–35. Autoantibodies to ILF2 and ILF3 have 
Figure 3. Screening the canine cohort for ILF3 and RBMX autoantibodies. A radio-ligand binding assay was 
used to screen for ILF3 (a) and RBMX (b) autoantibodies in dogs. The cutoff value for ILF3 was calculated 
from healthy controls as the mean + 5 SD. For RBMX, the mean + 7 SD was used as cutoff value because of 
a clear separation of negative and positive samples. All samples were analysed in duplicate. Autoantibody 
index = (sample value mean − negative control)/(positive control − negative control) * 100. NSDTR, Nova 
Scotia duck tolling retriever. IMRD ANAS, IMRD patients with speckled antinuclear antibodies (ANA) 
pattern. IMRD ANAH, IMRD patients with homogenous ANA pattern. IMRD ANAneg, IMRD patients without 
antinuclear antibodies. SRMA, steroid-responsive meningitis-arteritis.
Figure 4. Reactivity to ILF2, ILF3 and RBMX. The number of positive samples to ILF2, ILF3 and RBMX is 
presented in each field.
www.nature.com/scientificreports/
5Scientific RepoRts |  (2018) 8:4852  | DOI:10.1038/s41598-018-23034-w
previously been described in mice with induced lupus and as a rare finding in humans with autoimmune dis-
ease36,37. This highlights the fact that autoantibody targets are often conserved across species. The methods to 
identify the autoantibodies differ between ours and the previous studies.
In dogs, we found the autoantibodies to ILF2 and ILF3 exclusively in ANAS sera. The speckled ANA pattern is 
the most frequently observed ANA pattern in dogs8,20, and is also a major pattern observed in humans, where it is 
associated with disorders such as Sjögren’s syndrome, SLE, and systemic sclerosis31. Autoantibodies to ILF2 and/
or ILF3 were found in 52.0% of the 148 canine ANAS sera analysed in this study. In comparison, autoantibodies to 
RBMX, which has previously been described as an important autoantigen in dogs with ANAS, were found in only 
12.8% of the ANAS sera. Many dogs had autoantibodies to both ILF2 and ILF3, and our results from the immune 
competition suggest that this is not due to cross-reactivity but rather to specific binding.
To our knowledge, this is the first report of the autoantigens ILF2 and ILF3 in dogs. One explanation for why 
these autoantigens have not been previously reported could be that ILF2 (∼45 kDa) and RBMX (∼43 kDa) are 
of similar size. In a canine study by Welin Henriksson et al.38, immunoblot reactivity to a ∼43 kDa protein was 
frequently found in ANAS sera; the antigen was assumed to be RBMX based on the molecular mass. Similarly, 
Monier et al.15 describe autoantibodies to a ∼43 kDa protein in dogs with lupus-like disease and ANAS. In the 
light of the present study, it seems reasonable to assume, that at least some, if not most, of these samples, actually 
contained ILF2 autoantibodies. Soulard et al.39 also describe autoantibodies to a set of proteins of 45, 95, and 
110 kDa in dogs suffering from autoimmune disorders. These unidentified antigens, described to be present in the 
nucleoplasm and nucleoli of HEp-2 and HeLA cells, could have been ILF2 (45 kDa) and ILF3 (90 and 110 kDa40). 
Even though ILF2 and ILF3 are expressed in nucleoli41,42, autoantibodies in this area of the cell nucleus could not 
be detected by IIF using serum antibodies. One explanation for this could be that the concentration of serum 
antibodies was lower than that of the commercial antibodies.
Intriguingly, there was a strong breed difference regarding ILF2, ILF3 and RBMX autoantibodies. While ILF2 
and ILF3 were common antigen targets in NSDTRs and cocker spaniels, RBMX autoantibodies were exclusively 
found in German shepherd dogs, cross-breeds, and in one dog of unknown breed. This is in agreement with 
previous studies where RBMX has been described as an antigen mainly in German shepherd dogs with SLE or 
lupus-like disease43. Interestingly, in a study by Satoh et al.44, only two of 11 tested mouse strains developed ILF2 
and ILF3 autoantibodies upon treatment with pristane, a chemical that triggers lupus-like disease. In contrast, 
most of their mouse strains developed autoantibodies to well-known SLE autoantigens, like RNP and Sm, upon 
treatment with pristane. Thus, it seems like the genetic background is important for the development of autoan-
tibodies to ILF2 and ILF3.
While ILF2 and ILF3 autoantibodies are a common finding in dogs with autoimmune diseases, our screening 
of human sera is in line with previous reports that ILF2 and ILF3 autoantibodies are only occasionally present 
in humans. Satoh et al.36 identified ILF2 and ILF3 autoantibodies in only two of 1200 human sera. The study 
does not state if the investigated cohort included healthy controls or which different autoimmune disorders were 
assessed. Previously, Labrador et al.45 published a report of autoantibodies to a set of unidentified proteins in 
three patients with rheumatoid arthritis and features of systemic sclerosis. Satoh et al.36 later identified these 
patients as positive for ILF2 and ILF3 autoantibodies. Further investigation of larger cohorts of human patients 
with different and clearly defined autoimmune manifestations, is warranted to better understand the role of ILF2 
and ILF3 autoantibodies in human disease. Similarly, the clinical signs of ILF2 and ILF3 autoantibody-positive 
Figure 5. Sera from ILF2- and ILF3-positive patients and commercial ILF2 and ILF3 antibodies display 
a speckled ANA pattern. Indirect immunofluorescence microscopy images of HEp-2 cells incubated with 
sera from an ILF2- and ILF3-positive IMRD patient (a), a commercial polyclonal ILF2 antibody (b); and a 
commercial polyclonal ILF3 antibody (c). (a) In the nucleoplasm, fine tiny speckles can be observed and mitotic 
cells have unstained chromatin mass (⇨). The nucleoli are not stained (→). (b,c) In the nucleoplasm, fine tiny 
speckles can be observed and mitotic cells have unstained chromatin mass (⇨). Nucleoli are stained in many of 
the cells (→) but not all.
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dogs need to be thoroughly evaluated, to determine the diagnostic value of these autoantibodies as biomarkers. 
We could not find any associations between ILF2 and ILF3 autoantibodies and the clinical information that was 
available from the medical records of the NSDTRs with IMRD. It is possible that these autoantibodies could be 
used as a clinical biomarkers in other breeds, but there was no clinical information available in our study for these 
other breeds.
Several autoantigens have been previously identified in dogs by different approaches9,21,22,38,46–50. Here, we 
report the use of human protein arrays for the screening of canine autoantigens. To our knowledge, this type of 
discovery screening for autoantigens has not previously been applied to dogs and it allowed us to discover two 
new autoantigens, ILF2 and ILF3. The method is developed for screening a large number of antigen targets, but it 
has also some limitations. An antigen might fail to produce a signal due to technical factors, rather than absence 
of autoantibodies in the sample26. Furthermore, the proteins on the array are recombinant human ones, and the 
degree of protein conservation between humans and dogs varies. Therefore, negative results should not be inter-
preted as truly autoantibody-negative as autoantibodies usually reacts with conformationally sensitive epitopes 
that may be destroyed when presented on a surface26. For example, in our discovery screening, ILF3 was present 
on the array, but failed to generate an elevated signal in any of the samples that were ILF3-positive on RLBA. A 
positive result should also be interpreted with caution, since many initial reports of biomarkers cannot be repro-
duced51, and should be validated with an independent method. Here we used RLBA for validation, which presents 
the autoantigens in solution, and also allowed screening a larger number of samples. This would not have been 
possible in the discovery phase due to the substantial costs for the human protein arrays. In our experience, the 
RLBA is a sentitive and specific method for autoantibody detection, but we cannot rule out false negative samples, 
since different epitopes could potentially be present in vivo.
To conclude, by screening for a large number of autoantigen targets in a small, selected canine cohort, we 
identified ILF2, for the first time, as a canine autoantigen. By expanding the screen to include a larger number of 
canine samples from dogs of multiple breeds, we found that autoantibodies to ILF2, and the associated protein 
ILF3, were frequently present in canine ANAS sera. Furthermore, ILF2 and ILF3 autoantibodies were present in 
human patients with autoimmune disease, but as a rare finding. These autoantibodies have the potential to be 
used as diagnostic biomarkers in both species, but how to use this information needs to be further studied. We 
also showed that human protein arrays can be successfully used to identify canine autoantigens. The use of these 
arrays should lead to more autoantigen discoveries in veterinary medicine.
Materials and Methods
Canine subjects. The canine serum samples were collected between 2002 and 2014 and placed at −80 °C for 
long-term storage; some of the samples were temporarily stored at −20 °C before long-term storage. All experi-
ment were performed in accordance with relevant guidelines and regulations and ethical permission was obtained 
from the Uppsala Animal Ethical Committee and Swedish Board of Agriculture (C417/12, C418/12 and C15/16).
All of the IMRD patients were NSDTRs. The dogs diagnosed with IMRD displayed musculoskeletal signs 
with lameness, stiffness and pain from two or more joints on manipulation. The signs had been apparent for at 
least 14 days prior to sampling and were the main reason for the veterinary visit. The diagnostic tests to rule out 
other diseases varied between the dogs, but no other diseases than IMRD were suspected as the main cause of the 
clinical signs. All suspected IMRD cases were tested for ANA with IIF, as previously described20. Positive ANA 
and response to glucocorticoid treatment strengthened the diagnosis. Some of the dogs were under treatment 
with either non-steroid anti-inflammatory drugs or glucocorticoids at the time of sampling. Control dogs were 
considered healthy at the time of sampling based on clinical examination and owner interview.
Discovery cohort. In the protein array screen, sera from 21 NSDTRs were included: twelve with IMRD and 
nine healthy controls (Supplementary Table 1). The sera were selected from a larger cohort of NSDTRs that had 
been clinically characterised with respect to immune disease. The sera had also been tested for ANA with IIF. The 
twelve IMRD sera had also been tested for autoantibodies to 18 antigens associated with human autoimmune or 
rheumatic disorders using ELISA and line blot, as described previously21. All twelve IMRD sera tested positive 
on the IIF-ANA test – nine with a speckled pattern (ANAS), and three with a homogenous pattern (ANAH) 
(Supplementary Fig. 2). The nine ANAS sera and two of the ANAH sera were negative for all 18 tested antigens, 
while one of the ANAH sera showed both nucleosome and dsDNA reactivity with ELISA, and weak SS-A/Ro-52 
reactivity with line blot. The healthy controls were all ANA negative.
Validation cohort. In the validation of ILF2, and in the ILF3 and RBMX screening, the 21 serum sam-
ples from the protein array screen were tested together with 270 additional serum samples (but 269 for ILF3 
and 268 for RBMX, due to lack of sera), (Supplementary Table 2). In total, 29 ANAS sera from IMRD NSDTRs 
were screened for ILF2, ILF3 and RBMX autoantibodies. We also included 121 ANAS sera (120 for ILF3, 119 for 
RBMX) from a previous study21 consisting of sera from dogs of 43 different breeds. These included 20 German 
shepherd dogs (19 for ILF3, 18 for RBMX), 18 English and American cocker spaniels, 11 dogs of mixed breed, 7 
golden retrievers, and 65 of other or unknown breeds. Clinical information was unavailable for these 121 dogs, 
but sera had been sent to our laboratory for routine ANA testing, presumably because of suspicion of autoim-
mune disease.
Included as healthy controls were 84 dogs: 33 NSDTRs, 19 German shepherd dogs, and 32 of other breeds 
(13 border collies, 9 beagles, 6 labradors, 3 Australian shepherds, and 1 Boston terrier). We also included 57 
disease controls consisting of NSDTRs with IMRD and ANAH, IMRD without ANA, or steroid-responsive 
meningitis-arteritis, another immune-mediated disease described in the breed52. One of the dogs with 
steroid-responsive meningitis-arteritis was also included in the IMRD ANAS group. This dog was diagnosed with 
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steroid-responsive meningitis-arteritis at an age of 10 months and with IMRD at two years of age. Samples were 
taken 16 months apart for this dog.
Human subjects. Patients with SLE or Sjögren’s syndrome were included from the Rheumatology Clinic 
at Uppsala University Hospital, Sweden. As controls, sera from healthy blood donors from the Uppsala 
Bioresource53, and from previous studies23,24, were included. Sera were analysed for ILF2 (91 Sjögren’s syn-
drome, 38 SLE, 70 systemic sclerosis and 182 blood donors) and ILF3 (107 Sjögren’s syndrome, 38 SLE and 88 
blood donors) autoantibodies with RLBA. The study was approved by the local ethic committees in Uppsala and 
Stockholm (97358, 2006/217, 00-399, 2016/2553-31/2) and was performed in accordance with the Declaration of 
Helsinki and to relevant regulations. All participants gave their informed consent.
Indirect immunofluorescence microscopy. HEp-2 cells (RB-2100, Immunoconcepts) were incubated 
with rabbit polyclonal anti-ILF2 (HPA0007484, Atlas Antibodies) at a 1:100 dilution (2 μg/ml) and rabbit pol-
yclonal anti-ILF3 (HPA001897, Atlas Antibodies) at a 1:50 dilution (2 μg/ml) for 30 min. After 5 min of wash-
ing in PBS, cells were incubated with Alexa Fluor 488 conjugated goat anti-rabbit IgG (A-11034, Thermofisher 
Scientific) at a 1:200 dilution (10 μg/μl) for 30 min. The slides were washed with PBS and covered with coverslips 
before immunofluorescence imaging. HEp-2 cells were also incubated with canine patient sera at a 1:100 dilu-
tion followed by incubation with FITC conjugated rabbit anti-dog IgG at 1:100 dilution (F7884, Sigma-Aldrich). 
Images were taken using a Zeiss LSM 510 microscopy with the 40X objective.
Protein array screening. Protein arrays (HuProtTM v2 Human Proteome Arrays, CDI laboratories) were 
incubated with sera from dogs with IMRD and from healthy controls. The arrays were first incubated with block-
ing buffer (3% BSA in PBS-T) for 1 h, and thereafter with 5 ml diluted serum (1:200 in PBS-T (0.1%), 3% BSA 
and 5% milk powder) for 1 h. The arrays were then washed with PBS-T for 5 × 5 min. Next, arrays were incubated 
with Alexa Fluor 647 conjugated rabbit anti-dog IgG (304-605-00, Jackson ImmunoResearch) at a concentration 
of 0.04 μg/ml for 1 h, followed by washing with PBS-T for 5 × 5 min. Arrays were then incubated with anti-GST 
(Goat Anti-GST Dylight 550, 11254, Cayman Chemicals) at a concentration of 0.14 μg/ml for 1 h. The arrays 
were thereafter washed for 4 × 5 min with PBS-T followed by 1 × 5 min with PBS before being dipped 5 times in 
deionized water and centrifuged dry. Incubation and washing steps were performed in a four-chamber tray set 
at 50 rpm rotation at room temperature and arrays were covered from light starting with the anti-dog IgG incu-
bation step. The arrays were scanned using a Agilent G2505C microarray scanner (Agilent Technologies) and 
GenePix Pro 5.1.0.19 microarray software was used for alignment and data acquisition.
Radio-ligand binding assay. A RLBA was used to screen sera for autoantibodies to ILF2, ILF3 and RBMX. 
Human ILF3 cDNA in a pCMV6-Entry vector (RC214999, Origene) was used for in vitro transcription and trans-
lation of ILF3. Human ILF2 cDNA (RC201751, Origene) and human RBMX cDNA (RC 200777, Origene) were 
first subcloned into a pTNTTM vector (Promega, L5610) to enable in vitro transcription and translation. Sanger 
sequencing confirmed the respective clones as ILF2, ILF3 and RBMX.
In vitro transcription and translation was performed in the presence of 35S-methionine according to the man-
ufacturer’s protocol (Promega TNT Systems). Immunoprecipitation was performed in 96-well titration plates 
overnight at 4 °C at 300 rpm rotation. A positive standard (anti-ILF2 antibody, HPA007484; anti-ILF3 antibody, 
HPA0018979; anti-RBMX, HPA057707, Atlas Antibodies) and a negative standard of 4% BSA were included in 
each plate. To each well, 2.5 μl of sera and radiolabelled protein (~30,000 cpm) were added. All samples were 
analysed in duplicate. After incubation, the immune reaction was transferred to filter plates and serum antibodies 
were immobilised to Protein A Sepharose (nProtein A sepharose 4 Fast Flow, GE Healthcare) during 45 min of 
incubation at 4 °C at 300 rpm rotation. The plates were then washed 10 times with washing buffer (150 mM NaCl, 
20 mM Tris/HCl, 0.15% Tween 20 and 0.1% BSA) and dried. Scintillation solution (Optiphase supermix, Perkin 
Elmer) was added to all the wells (70 μl/well) and radioactivity was measured in a microbeta counter (1450 
MicroBeta TriLux, Wallac). Autoantibody index values were calculated according to the equation: Index = ((sam-
ple value mean − negative control)/(positive control − negative control)) × 100.
Immune competition assay. Serum from an ILF2- and ILF3 autoantibody-positive dog was selected and 
immunoreactivity was tested by RLBA in a dilution series from 1:20 to 1:40,960. The highest dilution that gave 
a clear positive result was 1:1,280 and was used for the experiments. Radioactive (labelled) and non-radioactive 
protein (unlabelled) were produced in parallel by in vitro transcription and translation. One unit of protein was 
represented by 30,000 cpm. Sera were allowed to react with 1 U of labelled protein and 0,1,2,4,8,16 and 32 U of 
unlabelled protein; reactivity was measured in the same way as described for the RLBA.
Statistical analyses. Statistical analyses of protein array data were performed on ln-transformed signal 
intensities. To identify antigen signals in the IMRD patients, cutoff values for each antigen were calculated from 
healthy controls as the mean + 3 SD. Signal-to-noise filtration was then performed for every sample by removing 
all signals below the mean + 3 SD for each sample (global filtration).
In the radio-ligand binding assay, cutoff values for ILF2 and ILF3 were calculated from healthy controls as the 
mean + 5 SD. For RBMX, there was a clear separation of samples that appeared negative and positive, and there-
fore a higher cutoff of the mean + 7 SD was applied.
All statistical calculations were performed in software R v.3.0 and Excel v.15.32.
Data availability. All relevant data are available from the authors upon request.
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